A new role for scientists in the biological weapons convention

Article Abstract:

The Biological Weapons Convention (BWC), the first agreement among nations that declared an entire category of weapons to be off limits is discussing measures to influence scientists' behavior, including professional codes of conduct and increased pathogen security. The impact of BWC on the life sciences include influencing the sharing of biological research samples, the formation of scientific collaborations or the ability to publish, strongly calls for the involvement of scientists, so that enacted measures would have the desired effect.

author: Gronvall, Gigi Kwik
Research and Development in the Physical, Engineering, and Life Sciences, Scientists

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA

Sarbanes-Oxley rules to be relaxed?

Article Abstract:

The US Securities and Exchange Commission (SEC) has heard the plea of small biotechs that are overwhelmed by Sarbanes-Oxley (SOX) financial accounting compliance costs and in May 2006 has announced his intentions to simplify unnecessary and expensive complexities. Despite such effort, SOX compliance costs have already diverted money from R&D budgets and has also discouraged access to capital for biotech companies, making an initial public offering (IPO) in the US a much more costly endeavor.

author: Lawrence, Stacy
Securities issued, listed, Securities, United States. Securities and Exchange Commission, Company securities

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA

Overhauling oversight: European drug legislation

Article Abstract:

The European Medicines Agency (EMEA) would implement a new legislative framework and several provisions that seek to provide incentives and streamline regulatory oversight of certain monoclonal antibody (mAb) and other biologic products. The provisions that have a significant impact on requirements for the application for marketing authorization, the approval process and the post marketing of mAb are presented.

author: Lincoln Tsang
Monoclonal antibodies, European Agency for the Evaluation of Medicinal Products

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


subjects list: United States, Laws, regulations and rules, Biotechnology industry, Biotechnology industries, Government regulation, Management, Company business management
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.